Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

NCT07754045 · Not yet recruiting

Last updated 2026-08-27

This clinical trial is testing whether adding LUM-201 to semaglutide improves physical function in older adults with obesity compared to semaglutide alone.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 202 people Planned (estimated).

Who can join Ages 60–84 · all sexes

Timeline Started 2027-02 · est. completion 2028-02

What this study is testing ClinicalTrials.gov NCT07754045 ↗

Description as written by the study sponsor.

This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages of 60 and 85 years that have mild functional impairment.

Treatments tested

LUM-201 Drug

Daily (AM) oral Tablet at 25 mg
Placebo Drug

Daily (AM) oral Tablet
Semagludtide Drug

Daily (AM) oral Tablet

Main thing measured	Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.
Sponsor	Lumos Pharma
Conditions studied	Obesity & Overweight
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07754045 ↗